Various elevated chemokines and their receptors could be biomarkers for evaluating immunotherapy effect in LAM and CCL2-CCR2 signaling could be promote the migration of LAM cells and influence tumor progression. The gene discussed is CCR2; the disease is lymphangioleiomyomatosis.